CYP1A1 and breast carcinoma: Increasing evidence has linked CYP1A1*2A A2455G MspI1 polymorphism with renal cell carcinoma, esophageal, lung, colorectal, and breast cancers with the prevalence of Ph+ve CML [35,36,37].